NextCure
Clinical-stage biopharmaceutical company focused on discovery and development of biologic therapeutics and antibody-drug conjugates for oncology and other diseases. Uses function-based discovery and translational approaches to identify cell-surface targets and advance candidates through preclinical studies and early-phase clinical trials. Engages in partnering and in-licensing for development and ADC linker/payload collaborations.
Industries
Nr. of Employees
medium (51-250)
Patents
Compositions and methods for modulating FLRT3 mediated signal transduction
US-12753229-B2
View Details
Compositions and methods for modulating FLRT3 mediated signal transduction
US-12753229-B2
View DetailsProducts
SIM0505
Antibody-drug conjugate targeting CDH6 with a topoisomerase I inhibitor payload; preclinical activity across multiple solid tumor models and in Phase 1 clinical testing.
LNCB74
Antibody-drug conjugate targeting B7-H4 with preclinical antitumor activity and current Phase 1 clinical development; designed to reduce toxicity while maintaining tumor killing.
NC410
Immunomedicine designed to block LAIR-1-mediated immune suppression and remodel collagen in the extracellular matrix to enhance T cell infiltration; studied in combination with PD-(L)1 therapy in Phase 1 studies.
NC525
Monoclonal antibody that binds LAIR-1 and induces killing of AML blast cells and leukemic stem cells; reported reduction of tumor burden in leukemia models and currently in Phase 1 dose escalation in AML.
NC605
Monoclonal antibody targeting siglec-15 (S15) designed to inhibit osteoclasts and prevent bone loss while promoting bone formation; developed for osteogenesis imperfecta and other bone disorders.
NC181
Monoclonal antibody designed to bind APOE4 to reduce amyloid plaques, suppress neuroinflammation and improve cerebral blood flow; developed for Alzheimer’s disease.
SIM0505
Antibody-drug conjugate targeting CDH6 with a topoisomerase I inhibitor payload; preclinical activity across multiple solid tumor models and in Phase 1 clinical testing.
LNCB74
Antibody-drug conjugate targeting B7-H4 with preclinical antitumor activity and current Phase 1 clinical development; designed to reduce toxicity while maintaining tumor killing.
NC410
Immunomedicine designed to block LAIR-1-mediated immune suppression and remodel collagen in the extracellular matrix to enhance T cell infiltration; studied in combination with PD-(L)1 therapy in Phase 1 studies.
NC525
Monoclonal antibody that binds LAIR-1 and induces killing of AML blast cells and leukemic stem cells; reported reduction of tumor burden in leukemia models and currently in Phase 1 dose escalation in AML.
NC605
Monoclonal antibody targeting siglec-15 (S15) designed to inhibit osteoclasts and prevent bone loss while promoting bone formation; developed for osteogenesis imperfecta and other bone disorders.
NC181
Monoclonal antibody designed to bind APOE4 to reduce amyloid plaques, suppress neuroinflammation and improve cerebral blood flow; developed for Alzheimer’s disease.
Services
Function-based screening and target identification in immune cell types for collaborative discovery projects.
Collaborative development opportunities for antibody-drug conjugates, including in-licensing and payload/linker partnerships.
Function-based screening and target identification in immune cell types for collaborative discovery projects.
Collaborative development opportunities for antibody-drug conjugates, including in-licensing and payload/linker partnerships.
Expertise Areas
- Immuno-oncology target discovery
- Antibody-drug conjugate development
- Monoclonal antibody therapeutics
- Preclinical translational development
Key Technologies
- Functional cell-based screening
- Primary human immune cell assays
- Animal models (mouse)
- Antibody-drug conjugates (ADC)
News & Updates
Company expanded access policy available for review.
Publication describing the mechanism of a LAIR-1–binding antibody with activity against leukemia (reference cited by the company).
Company expanded access policy available for review.
Publication describing the mechanism of a LAIR-1–binding antibody with activity against leukemia (reference cited by the company).